Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876029 | 0.86 | SLC7A5 (0.54) | SLC7A5LOXL2CYP4F2CYP4A11MEP1B | |
| SCHEMBL16355834 | 0.86 | SLC7A5 (0.57) | SLC7A5LOXL2CYP4F2CYP4A11MEP1B | |
| SCHEMBL14143797 | 0.85 | LOXL2 (0.64) | SLC7A5LOXL2CYP4F2CYP4A11MEP1B | |
| SCHEMBL16341027 | 0.85 | SLC7A5 (0.42) | SLC7A5HIF1ASMN1; SMN2ATMSTAT3 | |
| SCHEMBL12635581 | 0.85 | SLC7A5 (0.53) | SLC7A5LOXL2CYP4F2CYP4A11HIF1A | |
| SCHEMBL16355831 | 0.85 | SLC7A5 (0.53) | SLC7A5LOXL2CYP4F2CYP4A11MEP1B | |
| Hydrochloric Acid SCHEMBL17433718 | 0.85 | SLC7A5 (0.53) | SLC7A5LOXL2CYP4F2CYP4A11MEP1B | |
| SCHEMBL12301533 | 0.85 | SLC7A5 (0.65) | SLC7A5LOXL2CYP4F2CYP4A11MEP1B | |
| SCHEMBL31576604 | 0.84 | SLC7A5 (0.61) | SLC7A5LOXL2CYP4F2CYP4A11HIF1A | |
| SCHEMBL7611802 | 0.84 | SLC7A5 (0.58) | SLC7A5LOXL2CYP4F2CYP4A11MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | SLC7A5 1735/4885LOXL2 2517/4885CYP4F2 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.